Affibody CEO Describes Three-Year Growth Plan
Executive Summary
Sten Stovall chats with David Bejker, CEO of Solna, Sweden-based biotech Affibody AB, about development progress for the company's novel class of antibody mimetics, which he says have superior characteristics surpassing monoclonal antibodies (mAbs) and antibody fragments.